B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients

Critical Care Medicine

Volumn 36, Issue 11, 2008, Pages 3030-3037

  Post, Felix ^a   Weilemann, Ludwig S ^a   Messow, Claudia Martina ^a   Sinning, Christoph ^a   Münzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

B type natriuretic peptide; Sepsis; Septic myocardial depression; Septic shock

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CREATININE; DOBUTAMINE; NORADRENALIN; BIOLOGICAL MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE MARKER; FEMALE; GENDER; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; RISK; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL; BIOLOGICAL MODEL; BLOOD; HEART LEFT VENTRICLE FUNCTION; INTENSIVE CARE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ROC CURVE;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SEPSIS; SHOCK, SEPTIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 56049096490     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31818b9153     Document Type: Article

References (32)

1. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
2. Annane D, Aegerter P, Jars-Guincestre MC, et al: Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172
3. McLean AS, Huang SJ, Hyams S, et al: Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007; 35:1019-1026
4. Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483-490
5. Krishnagopalan S, Kumar A, Parrillo JE, et al: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8:376-388
6. Cunnion RE, Schaer GL, Parker MM, et al: The coronary circulation in human septic shock. Circulation 1986; 73:637-644
7. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al: Coronary hemodynamics and myo-cardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75:533-541
8. Mehta NJ, Khan IA, Gupta V, et al: Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004; 95:13-17
9. Hunt PJ, Espiner EA, Nicholls MG, et al: Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996; 81:3871-3876
10. Stanek B, Frey B, Hulsmann M, et al: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38:436-442
11. Hartmann F, Packer M, Coats AJ, et al: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110:1780-1786
12. Gardner RS, Ozalp F, Murday AJ, et al: N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24:1735-1743
13. Fisher C, Berry C, Blue L, et al: N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003; 89:879-881
14. Richards AM, Nicholls MG, Yandle TG, et al: Plasma N-terminal pro-brain natriuretic pep-tide and adrenomedullin: New neurohor-monal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929
15. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702
16. Charpentier J, Luyt CE, Fulla Y, et al: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665
17. Januzzi JL, Morss A, Tung R, et al: Natri-uretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: A prospective cohort study. Crit Care 2006; 10:R37
18. Meyer B, Huelsmann M, Wexberg P, et al: N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007; 35:2268-2273
19. Roch A, Allardet-Servent J, Michelet P, et al: NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33:1001-1007
20. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
21. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
22. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
23. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
24. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
25. Team RDC: R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2005
26. Kumar A, Osman J: Septic myocardial depression: No "no" to no? Crit Care Med 2001; 29:202-203
27. Rudiger A, Gasser S, Fischler M, et al: Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140-2144
28. Tomaru Ki K, Arai M, Yokoyama T, et al: Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myo-cytes. J Mol Cell Cardiol 2002; 34:649-659
29. Blankenberg S, McQueen MJ, Smieja M, et al: Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114: 201-208
30. Schnabel R, Lubos E, Rupprecht HJ, et al: B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: Results from the AtheroGene study. J Am Coll Cardiol 2006; 47:552-558
31. Troughton RW, Frampton CM, Yandle TG, et al: Treatment of heart failure guided by plasma aminoterminal brain natriuretic pep-tide (N-BNP) concentrations. Lancet 2000; 355:1126-1130
32. Mueller C, Scholer A, Laule-Kilian K, et al: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654